These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38844921)

  • 1. Systemic antibiotics for Pseudomonas aeruginosa infection in outpatients with non-hospitalised exacerbations of pre-existing lung diseases: a randomised clinical trial.
    Eklöf J; Alispahic IA; Armbruster K; Lapperre TS; Browatzki A; Overgaard RH; Harboe ZB; Janner J; Moberg M; Ulrik CS; Andreassen HF; Weinreich UM; Kjærgaard JL; Villadsen J; Fenlev CS; Jensen TT; Christensen CW; Bangsborg J; Ostergaard C; Ghathian KSA; Jordan A; Klausen TW; Nielsen TL; Wilcke T; Seersholm N; Sivapalan P; Jensen JS
    Respir Res; 2024 Jun; 25(1):236. PubMed ID: 38844921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial.
    Eklöf J; Alispahic IA; Sivapalan P; Wilcke T; Seersholm N; Armbruster K; Kjærgaard JL; Saeed MI; Nielsen TL; Browatzki A; Overgaard RH; Fenlev CS; Harboe ZB; Andreassen HF; Lapperre TS; Pedersen L; Johnsen S; Ulrik CS; Janner J; Moberg M; Heidemann M; Weinreich UM; Vijdea R; Linde H; Titlestad I; Johansson SL; Rosenvinge FS; Østergaard C; Ghathian KSA; Gundersen L; Christensen CW; Bangsborg J; Jensen TT; Sørensen VM; Ellingsgaard T; Datcu R; Coia JE; Bodtger U; Jensen JUS
    Trials; 2022 Sep; 23(1):817. PubMed ID: 36167555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antibiotics for bronchiectasis.
    Felix LM; Grundy S; Milan SJ; Armstrong R; Harrison H; Lynes D; Spencer S
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012514. PubMed ID: 29889304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotics against Pseudomonas aeruginosa for COPD exacerbation in ICU: a 10-year retrospective study.
    Planquette B; Péron J; Dubuisson E; Roujansky A; Laurent V; Le Monnier A; Legriel S; Ferre A; Bruneel F; Chiles PG; Bedos JP
    Int J Chron Obstruct Pulmon Dis; 2015; 10():379-88. PubMed ID: 25733827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients.
    Eklöf J; Sørensen R; Ingebrigtsen TS; Sivapalan P; Achir I; Boel JB; Bangsborg J; Ostergaard C; Dessau RB; Jensen US; Browatzki A; Lapperre TS; Janner J; Weinreich UM; Armbruster K; Wilcke T; Seersholm N; Jensen JUS
    Clin Microbiol Infect; 2020 Feb; 26(2):227-234. PubMed ID: 31238116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD005405. PubMed ID: 27412131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2013 Oct; (10):CD005405. PubMed ID: 24170644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of empirical anti-pseudomonal antibiotics for recurrent COPD exacerbation: a multicenter retrospective cohort study.
    Shiroshita A; Miyakoshi C; Tsutsumi S; Shiba H; Shirakawa C; Sato K; Matsushita S; Kimura Y; Tomii K; Ohgiya M; Kataoka Y
    Sci Rep; 2021 Oct; 11(1):20066. PubMed ID: 34625632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
    Serisier DJ; Bilton D; De Soyza A; Thompson PJ; Kolbe J; Greville HW; Cipolla D; Bruinenberg P; Gonda I;
    Thorax; 2013 Sep; 68(9):812-7. PubMed ID: 23681906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotics for exacerbations of chronic obstructive pulmonary disease.
    Vollenweider DJ; Frei A; Steurer-Stey CA; Garcia-Aymerich J; Puhan MA
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010257. PubMed ID: 30371937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.
    McDonnell MJ; Jary HR; Perry A; MacFarlane JG; Hester KL; Small T; Molyneux C; Perry JD; Walton KE; De Soyza A
    Respir Med; 2015 Jun; 109(6):716-26. PubMed ID: 25200914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To
    Montón C; Prina E; Pomares X; Cugat JR; Casabella A; Oliva JC; Gallego M; Monsó E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2365-2373. PubMed ID: 31802860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors.
    Gallego M; Pomares X; Espasa M; Castañer E; Solé M; Suárez D; Monsó E; Montón C
    BMC Pulm Med; 2014 Jun; 14():103. PubMed ID: 24964956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.